Publications by authors named "H Sanoff"
Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy has demonstrated efficacy in combination with radiation. In this issue, Xiao et al.
View Article and Find Full Text PDFArticle Synopsis
- * The design of a new NCI-sponsored randomized trial aims to determine the best chemotherapy regimen for patients who achieve a clinical complete response (cCR) after TNT, potentially allowing for a "watch and wait" strategy instead of immediate surgery.
- * The trial will enroll up to 760 patients with specific LARC criteria and will evaluate the effectiveness of long-course chemoradiation followed by different consolidation chemotherapy regimens, with patient outcomes being monitored over time.
Article Synopsis
- FOLFIRI, a treatment for metastatic colorectal cancer, was tested using a pharmacogenomic strategy to tailor irinotecan doses based on UGT1A1 genotypes to see if it could improve progression-free survival (PFS).
- In a study with 100 participants, results showed a median PFS of 12.5 months, which was shorter than expected, with variations in PFS based on genotype.
- Although a tailored irinotecan strategy showed modest improvements in PFS for certain genotypes, it did not significantly change overall treatment outcomes and shouldn't replace current standard practices for first-line treatment.
Introduction: Standard investigator-based adverse events (AE) assessment is via CTCAE for clinical trials. However, including the patient perspective through PRO (patient-reported outcomes) enhances clinicians' understanding of patient toxicity and fosters early detection of AEs. We assessed longitudinal integration of PRO-CTCAE within clinical workflow in a phase II trial.
View Article and Find Full Text PDF